translation agency

CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update
GLOBAL: Bristol Adds Medicine to Patent Pool for AIDS Drugs
By Ben Hirschler
December 13, 2013
Reuters (12.12.2013)

Reuters recently reported that an agreement announced on December 12 by the UN-supported Medicines Patent Pool detailing Bristol-Myers Squibb’s sharing of intellectual property rights is the first to cover an HIV drug meant for use if patients develop resistance to initial treatments. The licensing agreement will allow generic drug firms around the world to manufacture more affordable versions of atazanavir, which Bristol sells under the brand name Reyataz. The move will make such second-line treatments more widely available in poorer countries. The World Health Organization estimates that more than 1 million individuals will be on these treatments by 2016.